Risk factors associated with severe outcomes in adult hospitalized patients according to influenza type and subtype
Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Ángela Domı́nguez(Instituto de Salud Carlos III), Arantxa Romero-Tamarit(Universitat Autònoma de Barcelona), Mireia Jané(Generalitat de Catalunya), Núria Soldevila(Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública), Cristina Rius(Centro de Investigación Biomédica en Red), Pere Godoy(Servicio Canario de la Salud), Núria Torner(Centro de Investigación Biomédica en Red)
Cited by 146
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
|Critical Care|2009|382
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334